Financial Data and Key Metrics Changes - Total revenues for Q4 2020 were $21.0 million, up 12.8% year-over-year, with $16.7 million from Performance Enzymes and $4.3 million from Novel Biotherapeutics [38] - Product revenue for Q4 2020 was $12.2 million, a 150% increase from $4.9 million in the prior year, marking the highest quarterly product revenue [39] - Gross margin on product revenue for Q4 2020 was 52.0%, compared to 30.2% in Q4 2019, attributed to a favorable product mix [39] - Total revenues for fiscal 2020 were $69.1 million, a 1% increase from 2019, with $48.1 million from Performance Enzymes and $21.0 million from Novel Biotherapeutics [42] - Product revenues for fiscal 2020 were $30.2 million, up 3% from 2019, with a gross margin of 54.5%, up from 46.9% in 2019 [43][44] Business Line Data and Key Metrics Changes - Performance Enzymes segment generated $16.7 million in Q4 2020, compared to $17.1 million in Q4 2019, while Novel Biotherapeutics increased from $1.6 million to $4.3 million in the same period [38] - The Performance Enzymes segment faced challenges due to COVID-19, impacting R&D service revenues, while Novel Biotherapeutics benefited from Takeda's upfront payment and R&D services [42] - The company had 15 sustainable manufacturing customers contributing over $100,000 in average quarterly revenue in 2020, up from 13 in 2019 [11] Market Data and Key Metrics Changes - The company is expanding into the life science tools market, generating $3.6 million in revenue in 2020, with expectations for growth in 2021 [23][72] - The partnership with Tate & Lyle in the food sector is expected to drive significant growth, with enzymes for sweeteners showing promising results [19][107] Company Strategy and Development Direction - Codexis aims to leverage its enzyme engineering capabilities to penetrate multiple markets, including sustainable manufacturing, life science tools, and biotherapeutics [9][30] - The company plans to expand its R&D capacity by increasing the number of enzyme discovery teams from 16 to approximately 25 by 2022 [88] - Codexis is focusing on self-funded R&D in life science tools and biotherapeutics, aiming to retain more value from successful enzyme developments [92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth of 19% to 23% in 2021, driven primarily by the Performance Enzymes segment [46] - The company anticipates product sales between $36 million and $39 million in 2021, with gross margins expected to remain strong at 54% to 58% [48] - Management highlighted the potential for significant growth in the life science tools market and the biotherapeutics pipeline, with multiple catalysts expected to drive growth [52][100] Other Important Information - Codexis completed a follow-on offering in December 2020, raising $81 million, resulting in a cash balance of $149.1 million, positioning the company well for growth opportunities [45] - The company is set to occupy a new facility in Q4 2021, which will enhance its R&D capabilities [50] Q&A Session Summary Question: Can you break down the components of product revenue growth in 2021? - Management indicated growth will come from stable sales to Merck for Januvia, increased demand from recent customers like Allergan and Urovant, and new sales in the life science tools market [58][60] Question: What is the expected revenue ramp for life sciences in 2021? - Management expects significant growth from recently launched products, particularly DNA and RNA polymerases, with sales anticipated to be stronger in the second half of the year [70][72] Question: What are the clinical milestones expected in the Biotherapeutics segment? - The initiation of the first clinical trial for CDX-7108 is expected in Q3 2021, with additional data to be shared as it becomes available [99][100] Question: What proportion of current product revenues comes from the food segment? - Management noted that the food sector is growing, particularly through the partnership with Tate & Lyle, which is expected to contribute significantly to revenue [107]

CODEXIS® We engineer enzymes to improve health… of people and the planet Q4 & FY'2020 Results February 25, 2021 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achieveme ...

Corporate Presentation John Nicols, CEO & President November 2020 CODEXIS® Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to differ materially from those ex ...

Codexis, Inc. (NASDAQ:CDXS) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Jody Cain - LHA John Nicols - President and CEO Ross Taylor - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Stephens Operator Good day, and welcome to Codexis Third Quarter Financial Results Conference Call. [Operator Instructions] Please note that today's event is being recorded. At this time, I would like to turn the confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ____________________ ...

Codexis, Inc. (NASDAQ:CDXS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Bruce Voss - Lippert/Heilshorn & Associates John Nicols - President, CEO & Director Ross Taylor - SVP & CFO Conference Call Participants Matthew Hewitt - Craig-Hallum Brandon Couillard - Jefferies Mason Carrico - Stephens Inc. Operator Good afternoon, and welcome to the Codexis Second Quarter Financial Results Conference Call. [Operator Instructions]. I would now like to turn the conference over to Br ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

[PART I. FINANCIAL INFORMATION](index=2&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=2&type=section&id=ITEM%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for the quarter ended March 31, 2020, including balance sheets, statements of operations, stockholders' equity, and cash flows, along with detailed notes on accounting policies and agreements [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2020, total assets slightly increased to $149.5 million, while cash and cash equivalents decreased, and total liabilities rose to $50.4 million primarily due to deferred revenue, leading to a decrease in total stockholders' equity to $99.1 million Condensed Consolidated Balance Sheet Data (in thousands) | Account | March 31, 2020 | December 31, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $87,327 | $90,498 | | Total current assets | $114,562 | $114,205 | | Total assets | $149,472 | $149,073 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $22,282 | $15,388 | | Total liabilities | $50,406 | $43,556 | | Total stockholders' equity | $99,066 | $105,517 | | Total liabilities and stockholders' equity | $149,472 | $149,073 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2020, total revenues decreased to $14.7 million, resulting in a wider net loss of $7.7 million, or ($0.13) per share, compared to a $5.1 million net loss in the prior-year quarter Statement of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Total revenues | $14,670 | $15,583 | | Loss from operations | ($7,827) | ($5,239) | | Net loss | ($7,652) | ($5,136) | | Net loss per share, basic and diluted | ($0.13) | ($0.09) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity decreased from $105.5 million at the start of the quarter to $99.1 million by March 31, 2020, primarily due to the $7.7 million net loss, partially offset by $2.2 million in employee stock-based compensation Changes in Stockholders' Equity (in thousands) | Description | Three Months Ended March 31, 2020 | | :--- | :--- | | Balance as of January 1, 2020 | $105,517 | | Net loss | ($7,652) | | Employee stock-based compensation | $2,169 | | Taxes paid related to net share settlement | ($1,007) | | Balance as of March 31, 2020 | $99,066 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2020, net cash used in operating activities improved to $1.4 million, while investing activities used $0.8 million and financing activities used $1.0 million, resulting in a total net decrease in cash of $3.2 million Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,425) | ($2,851) | | Net cash used in investing activities | ($761) | ($445) | | Net cash used in financing activities | ($1,019) | ($2,082) | | Net decrease in cash, cash equivalents and restricted cash | ($3,205) | ($5,378) | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's business, accounting policies, and financial results, covering its CodeEvolver® platform, revenue recognition, collaborative agreements, segment performance, and the initial impacts of the COVID-19 pandemic - The company discovers, develops, and sells proteins using its proprietary **CodeEvolver®** protein engineering technology platform, which leverages artificial intelligence. It operates in two segments: Performance Enzymes (for pharmaceuticals, food, diagnostics) and Novel Biotherapeutics (for developing drug candidates)[23](index=23&type=chunk)[24](index=24&type=chunk)[31](index=31&type=chunk) - The company adopted new accounting standards on January 1, 2020, including ASU 2016-13 for credit losses (CECL model) and ASU 2017-04 for simplifying goodwill impairment testing, with no material impact on financial statements[61](index=61&type=chunk)[62](index=62&type=chunk) - In March 2020, the company entered into a strategic collaboration and license agreement with Takeda to develop gene therapies, receiving an **$8.5 million** upfront payment, with **$2.2 million** recognized as research and development revenue for Q1 2020[34](index=34&type=chunk)[108](index=108&type=chunk)[111](index=111&type=chunk) - The COVID-19 pandemic resulted in approximately **$0.6 million** of deferred research and development revenue for Q1 2020 and caused the temporary closure of its Redwood City facilities, with the full future impact remaining uncertain[38](index=38&type=chunk)[154](index=154&type=chunk) - In April 2020, the company achieved a technology transfer milestone under its agreement with Novartis, entitling it to a **$4.0 million** payment[176](index=176&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=ITEM%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the financial results for Q1 2020, highlighting a decrease in total revenue driven by lower product sales, offset by growth in R&D revenue from new collaborations, and details the company's liquidity, capital resources, and the initial business impact of the COVID-19 pandemic [Results of Operations](index=39&type=section&id=MD%26A_Results%20of%20Operations) Total revenues for Q1 2020 decreased by 6% to $14.7 million, primarily due to a 36% drop in product revenue, partially offset by a 26% increase in R&D revenue, leading to a 49% increase in net loss to $7.7 million Results of Operations Summary (in thousands) | Metric | Q1 2020 | Q1 2019 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $14,670 | $15,583 | ($913) | (6)% | | Product revenue | $5,100 | $7,988 | ($2,888) | (36)% | | R&D revenue | $9,570 | $7,595 | $1,975 | 26% | | Cost of product revenue | $2,541 | $4,391 | ($1,850) | (42)% | | Research and development | $10,967 | $8,016 | $2,951 | 37% | | Selling, general and administrative | $8,989 | $8,415 | $574 | 7% | | Net loss | ($7,652) | ($5,136) | ($2,516) | (49)% | - Product gross margin improved to **50%** in Q1 2020 from **45%** in Q1 2019 due to a more favorable product mix[241](index=241&type=chunk) - The increase in R&D revenue was primarily driven by the Novartis CodeEvolver® Agreement and the Takeda Agreement, partially offset by lower revenue from Nestlé Health Science compared to the prior year[237](index=237&type=chunk) - The increase in R&D expenses was mainly due to higher costs for outside services related to Chemistry, Manufacturing, and Controls (CMC), regulatory expenses, and increased headcount[243](index=243&type=chunk) [Liquidity and Capital Resources](index=48&type=section&id=MD%26A_Liquidity%20and%20Capital%20Resources) As of March 31, 2020, the company held $87.3 million in cash and cash equivalents and $92.3 million in working capital, believing these resources, along with an undrawn $15.0 million credit facility, are sufficient to fund operations for at least the next 12 months, despite uncertain COVID-19 impacts Liquidity Summary (in thousands) | Metric | March 31, 2020 | December 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $87,327 | $90,498 | | Working capital | $92,280 | $98,817 | - Net cash used in operating activities for Q1 2020 was **$1.4 million**, an improvement from **$2.9 million** in Q1 2019[277](index=277&type=chunk) - The company has a credit facility allowing for up to **$10.0 million** in term loans and a **$5.0 million** revolving line of credit, with no amounts drawn as of March 31, 2020[267](index=267&type=chunk) - The company received an **$8.5 million** upfront payment from Takeda in March 2020 as part of a new strategic collaboration[270](index=270&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=54&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's market risks are primarily from interest rate fluctuations on its undrawn variable-rate credit facility and limited foreign currency exchange rate changes, with a hypothetical 10% unfavorable exchange rate shift potentially leading to a $0.1 million loss - The company has a credit facility with variable interest rates, but since no amounts were drawn as of March 31, 2020, there was no impact from interest rate changes[296](index=296&type=chunk) - Foreign currency risk is present due to non-functional currency denominated monetary assets; a hypothetical **10%** unfavorable change in exchange rates would result in a potential loss of approximately **$0.1 million**[297](index=297&type=chunk) [Controls and Procedures](index=55&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2020, with no material changes to internal control over financial reporting, aside from minor modifications for remote work due to COVID-19 and new accounting standards adoption - The principal executive officer and principal financial officer concluded that disclosure controls and procedures were effective as of March 31, 2020[300](index=300&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, internal control over financial reporting. Minor modifications were made due to COVID-19 shelter-in-place orders[301](index=301&type=chunk) [PART II. OTHER INFORMATION](index=56&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=56&type=section&id=ITEM%201.%20Legal%20Proceedings) The company reports that it is not currently a party to any material pending litigation or other material legal proceedings - The company is not currently a party to any material pending litigation or other material legal proceedings[305](index=305&type=chunk) [Risk Factors](index=56&type=section&id=ITEM%201A.%20Risk%20Factors) This section highlights significant risks from the ongoing COVID-19 pandemic, detailing potential adverse effects on business operations, supply chains, clinical trials, and employee availability, leading the company to withdraw its full-year 2020 financial guidance due to uncertainty - The primary updated risk factor is the ongoing COVID-19 pandemic, which may adversely affect business, results of operations, and financial condition[307](index=307&type=chunk) - The pandemic has caused disruptions including the temporary closure of the Redwood City facilities, potential supply chain delays, and challenges in conducting R&D and clinical trials[310](index=310&type=chunk)[311](index=311&type=chunk) - Due to the uncertainty surrounding the impact of COVID-19, the company has withdrawn its full-year 2020 financial guidance[313](index=313&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=57&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[314](index=314&type=chunk) [Exhibits](index=58&type=section&id=ITEM%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the Strategic Collaboration and License Agreement with Takeda, a letter agreement with GlaxoSmithKline, officer certifications, and iXBRL data files - Key exhibits filed include the Strategic Collaboration and License Agreement with Takeda and various officer certifications required by the SEC[319](index=319&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34705 | --- | --- | |----------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 _____________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) __________________ ...